(News 24h) – Vaccine from US-German company Pfizer-BioNTech announced the delivery of insufficient quantity, Europe criticized and threatened.
After Pfizer has charged 6 doses in each vial of COVID-19 vaccine, instead of the agreed 5 doses, Sweden is working to clarify how many doses it should pay.
|Pfizer’s COVID-19 vaccine is not enough for Europe.|
Currently, Sweden wants the European Union Commission (EU) and Pfizer to reach an agreement on the number of doses per bottle.
“We told the company that we must suspend payment of the bill until the number of doses of the vaccine is clarified,” said epidemiologist Anders Tegnell.
Earlier this month, the European Pharmaceutical Regulatory Authority authorized the extraction of a sixth dose from the vaccine vials, in order to increase the number of injections available at a time of short supply.
To extract the 6th dose, a special needle is required, leaving only a small amount of the solution after injection.
“This is unacceptable. If a country can only extract 5 doses, then that country will receive less doses for the same price,” – Dagens Nyheter quoted vaccine coordinator of the country. Swedish Richard Bergstrom.
A spokesperson for the Swedish Health Service said she was unable to immediately comment on the report. This agency is originally the unit that handles invoices related to the purchase of the Swedish vaccine COVID-19.
Sweden buys more vaccines than it needs from the EU joint purchase program, then passes the supplement over to neighboring Norway, which is not a member of the bloc.
Sweden’s warning to Pfizer regarding bills of payment is the latest news of the US pharmaceutical company in the context of a disruption to European shipments on suspicions of low quality.
During this time, Anglo-Swedish pharmaceutical company AstraZeneca also delayed the delivery of vaccine to Europe.
EU Health Commissioner Stella Kyriakides on Jan. 25 expressed dissatisfaction over the talks with AstraZeneca as the manufacturer announced “its intention to provide significantly less dosage in the coming weeks than the deal and notification”.
The European Union has ordered 300 million doses of the AstraZeneca vaccine, which can be approved as soon as this week, with the option to purchase an additional 100 million.
The company said production was hampered by a production malfunction. The initial volume will be lower than initially expected due to reduced production at one production site in our European supply chain. million doses in February and March for the European Union, as we continue to increase production volumes. “
The Russian vaccine was once again reviewed and welcomed in Europe in this context.
|Vaccine Sputnik V from Russia|
According to CNBC, on January 21, the COVID-19 vaccine called Sputnik of Russia recorded a new milestone in the world’s recognition when it was approved by Hungary and the United Arab Emirates (UAE). used in an emergency situation.
These are the first two countries of the European Union (EU) and the Gulf bloc to ratify the Russian COVID-19 vaccine.
The spokesman of the Hungarian President, Viktor Orban, confirmed the information, and said that if Hungary reached an agreement to buy, it would be the first country in the EU to receive the Russian COVID-19 vaccine.
However, the EU pharmaceutical regulator has not yet approved the Sputnik V vaccine.
The Russian Direct Investment Fund (RDIF) has applied for a license for the COVID-19 vaccine to the EU Pharmaceutical Regulatory Authority and hopes to be assessed in February 2021. Sources from the EU showed that the Union appears to approve the Sputnik V profile by the end of January as other vaccines for Europe are limited in number, especially a change in deliveries. by Pfizer and AstraZeneca.
A third Russian vaccine can fix any variation
Russian Prime Minister Mikhail Mishustin said Russia’s third vaccine against the COVID-19 virus will be in circulation within the next few months, according to TASS.
“The Ministry of Health has received the registration procedure for another vaccine from the Chumakov Center, which is already our scientists’ third product.
Over the next few months, it will also circulate among the civilians. This will allow for an expanded vaccination, making it more accessible, meaning more people protection against the corona virus. ”
The Russian Prime Minister reiterated that currently Sputnik V is used mainly in mass vaccination.
“Next month, we will move to large-scale production of the EpiVacCorona vaccine. This vaccine has already begun to enter civilian circulation. The government has allocated more than 2 billion rubles (about more than $ 26 million) to produce.” “- Mr. Mishustin added.
Vaccine studied by the Chumakov Center “KoviVac” will be completed in mid-February. This vaccine is produced by traditional methods, on the basis of an inactivated virus. The use of the vaccine will allow the body to better recognize the SARS-CoV-2 virus and when exposed to the virus, the defense mechanism is activated.
At the same time, to prepare the vaccine, Russian scientists used the entire virus, not just one fragment of the genome, thus ensuring the vaccination’s effectiveness against any mutations of the virus. SARS-CoV-2.
Another advantage of this vaccine is its ability to vaccinate the most vulnerable groups, children and the elderly with chronic diseases.
Clip simulating the COVID-19 vaccine activity of Pfizer-BioNTech: